Top Markets
Coin of the day
MGC Pharmaceuticals Limited MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited

MXC
Classificação em ações #39836
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established... MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
Preço da ação
$0.27239819
Última sincronização: 2024-04-29
Valor de mercado
$330.42K
Variação (1 dia)
0.52%
Variação (1 ano)
0.00%
País
AU
Negociar MGC Pharmaceuticals Limited (MXC)

Categoria

EPS de MGC Pharmaceuticals Limited (MXC)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da MGC Pharmaceuticals Limited, o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da MGC Pharmaceuticals Limited de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes